Picromycin is a 14-membered macrolide antibiotic and Prolylendopeptidase (PREP) inhibitor. Pikromycin shows activity against gram-positive bacteria including mycobacteria.
S 17092 (S 17092-1) is a highly effective inhibitor of cerebral prolyl-endopeptidase (PEP), displaying an IC50 value of 1.2 nM. It is utilized in research focused on understanding memory impairment and cognitive disorders associated with cerebral aging [1].
JTP-4819 is a potent and selective prolylendopeptidase (PEP) inhibitor with potential for treating Alzheimer's disease. At nanomolar concentration, JTP-4819 inhibited the degradation of substance P, arginine-vasopressin, and thyrotropin-releasing hormone by PEP in supernatants of the rat cerebral cortex and hippocampus. Repeated administration of JTP-4819 reversed the aging-induced decrease in brain substance P-like and thyrotropin-releasing hormone-like immunoreactivity, suggesting that this drug may be able to improve the imbalance of peptidergic neuronal systems that develops with senescense by inhibiting PEP activity. JTP-4819 increased acetylcholine release from the frontal cortex and hippocampus, regions closely associated with memory, in both young and aged rats.